JP2003522145A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522145A5
JP2003522145A5 JP2001557560A JP2001557560A JP2003522145A5 JP 2003522145 A5 JP2003522145 A5 JP 2003522145A5 JP 2001557560 A JP2001557560 A JP 2001557560A JP 2001557560 A JP2001557560 A JP 2001557560A JP 2003522145 A5 JP2003522145 A5 JP 2003522145A5
Authority
JP
Japan
Prior art keywords
nicotine
methylpyrazole
piperidino
dichlorophenyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2001557560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522145A (ja
Filing date
Publication date
Priority claimed from FR0001682A external-priority patent/FR2804604B1/fr
Application filed filed Critical
Publication of JP2003522145A publication Critical patent/JP2003522145A/ja
Publication of JP2003522145A5 publication Critical patent/JP2003522145A5/ja
Ceased legal-status Critical Current

Links

JP2001557560A 2000-02-09 2001-02-07 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用 Ceased JP2003522145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
FR00/01682 2000-02-09
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009217269A Division JP2010018622A (ja) 2000-02-09 2009-09-18 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用

Publications (2)

Publication Number Publication Date
JP2003522145A JP2003522145A (ja) 2003-07-22
JP2003522145A5 true JP2003522145A5 (https=) 2006-01-05

Family

ID=8846875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001557560A Ceased JP2003522145A (ja) 2000-02-09 2001-02-07 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用
JP2009217269A Withdrawn JP2010018622A (ja) 2000-02-09 2009-09-18 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009217269A Withdrawn JP2010018622A (ja) 2000-02-09 2009-09-18 セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用

Country Status (32)

Country Link
US (2) US6930122B2 (https=)
EP (1) EP1257275B1 (https=)
JP (2) JP2003522145A (https=)
CN (1) CN1250220C (https=)
AR (1) AR028505A1 (https=)
AT (1) ATE292467T1 (https=)
AU (1) AU781827B2 (https=)
BG (2) BG110386A (https=)
BR (1) BR0108126A (https=)
CA (1) CA2397262C (https=)
CZ (1) CZ296685B6 (https=)
DE (1) DE60109903T2 (https=)
DK (1) DK1257275T3 (https=)
EE (1) EE04836B1 (https=)
ES (1) ES2240416T3 (https=)
FR (1) FR2804604B1 (https=)
HU (1) HU225328B1 (https=)
IL (1) IL150710A0 (https=)
IS (1) IS6450A (https=)
MX (1) MXPA02007766A (https=)
NO (1) NO324521B1 (https=)
NZ (1) NZ519924A (https=)
PL (1) PL201685B1 (https=)
PT (1) PT1257275E (https=)
RS (1) RS50404B (https=)
RU (1) RU2257207C2 (https=)
SI (1) SI1257275T1 (https=)
SK (1) SK284952B6 (https=)
TW (1) TWI243677B (https=)
UA (1) UA72783C2 (https=)
WO (1) WO2001058450A2 (https=)
ZA (1) ZA200205317B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
US8129253B2 (en) 2001-08-13 2012-03-06 Finisar Corporation Providing current control over wafer borne semiconductor devices using trenches
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
EP1490043A4 (en) 2002-03-26 2007-05-30 Merck & Co Inc SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005044785A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
JP2008505965A (ja) 2004-07-12 2008-02-28 カディラ ヘルスケア リミティド カンナビノイド受容体修飾因子としての三環式ピラゾール誘導体
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
AR059021A1 (es) * 2006-01-18 2008-03-05 Schering Corp Moduladores de receptores cannabinoides
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
WO2008046905A1 (en) * 2006-10-20 2008-04-24 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US8623873B2 (en) * 2007-06-28 2014-01-07 Intervet Inc. Substituted piperazines as CB1 antagonists
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Similar Documents

Publication Publication Date Title
JP2003522145A5 (https=)
RU2002118309A (ru) Применение антагониста центральных каннабиноидных рецепторов для приготовления лекарств, предназначенных для облегчения прекращения курения
MX358515B (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y. manejo de sindromes mielodisplasicos.
HUP0001894A2 (hu) N-Piperidino-3-pirazolkarboxamid-származékot, sóját vagy szolvátját tartalmazó orálisan adagolható gyógyszerkészítmény
PE20081649A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
HRP20030249A2 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
CA2376226A1 (en) New formulation
TNSN04095A1 (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
EP1386606A4 (en) INJECTION STABLE, HIGH CONCENTRATION WITH A PYRAZOLON DERIVATIVE
WO2002016312A3 (de) NEUE VERBINDUNGEN, DIE FAKTOR Xa-AKTIVITÄT INHIBIEREN
NZ508371A (en) Therapeutic anti-cold agent containing isomalt as an active ingredient
ATE324112T1 (de) Topische behandlung bei der mastalgie
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
HRP20020989B1 (hr) Enantiomer 1,2-aneliranog kinolina koji inhibira farnezil transferazu
KR20070112266A (ko) 칸나비노이드 수용체 길항제 화합물과 항정신병제의조합물을 함유하는 제약 조성물
CA2325282A1 (en) Use of apo b secretion/mtp inhibitors
US20190336636A1 (en) Dissolvable effervescent toilet deodorizer and method of use
CL2008001176A1 (es) Combinacion farmaceutica que comprende pregabalina y 1-(2-etoxietil)-5-[etil(metil)amino]-n-mesil-7-[(4-metil-2-piridil)amino]-1h-pirazol[4,3-d]pirimidina-3-carboxamida; composicion farmaceutica; y uso de la combinacion para el tratamiento del dolor.